Broadcasting from EULAR 2024: Dazodalibep Significantly Improves Disease Activity in Rheumatoid Arthritis
Dazodalibep significantly improves disease activity and swollen and tender joint counts in patients with moderate-to-severe active rheumatoid arthritis (RA), according to new findings from the Phase 2 MIDORA clinical trial.
The drug, a non-antibody fusion protein that targets CD40L, also reduced biomarkers of T- and B-cell costimulatory blockage and inhibited germinal center formation activity and autoantibody production, in a population with RA.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
